Dinaciclib (SCH727965)

Description: Dinaciclib (formerly known as SCH727965) is a novel, selective and potent cyclin-dependent kinases (CDK) inhibitor for CDK2, CDK5, CDK1 and CDK9 with IC50 of 1 nM, 1 nM, 3 nM and 4 nM in cell-free assays, respectively. It also blocks thymidine (dThd) DNA incorporation and has potential antineoplastic activity. Compared with flavopiridol, Dinaciclib exhibits superior activity with an improved therapeutic index. Dinaciclib induced regression of established solid tumors in a range of mouse models following intermittent scheduling of doses below the maximally tolerated level.

References: Mol Cancer Ther. 2010 Aug; 9(8):2344-53; Mol Cancer Ther. 2011 Apr; 10(4):591-602.